Loading clinical trials...
Loading clinical trials...
J-Valve to Treat Aortic Regurgitation Via Transcatheter Therapy
The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR). A Cardiac Magnetic Resonance (CMR) sub-study will examine if intervention for AR translates to improved ventricular remodeling, the impact of LV remodeling on clinical outcomes and quality of life, as well as volumetric and myocardial differences between genders.
This is a prospective, single arm, multi-center, interventional pivotal study that will enroll up to 194 subjects in up to 35 investigational sites, predominantly in the United States and up to 7 in Canada, Europe, and Japan. Of the 194 subjects, the CMR imaging sub-study will include up to 75 subjects with severe AR already confirmed by TTE. Additionally, up to 40 roll-in subjects may be treated to enable clinical experience and exposure to the device while allowing a reasonable learning curve. The subjects will then be followed 5-years post-procedure of the J-Valve TF System.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
HonorHealth Research & Innovation Institute
Scottsdale, Arizona, United States
Cedars Sinai
Los Angeles, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Bay Area Structural Heart at Sutter Health
San Francisco, California, United States
University of California San Francisco
San Francisco, California, United States
UC Health Northern Colorado (Medical Center of the Rockies)
Loveland, Colorado, United States
Washington Hospital Center DC
Washington D.C., District of Columbia, United States
NCH Rooney Heart Institute
Naples, Florida, United States
Emory University Atlanta
Atlanta, Georgia, United States
Piedmont
Atlanta, Georgia, United States
Start Date
October 17, 2024
Primary Completion Date
February 1, 2028
Completion Date
February 1, 2032
Last Updated
February 18, 2026
194
ESTIMATED participants
J-Valve Transfemoral (TF) System
DEVICE
Lead Sponsor
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Collaborators
NCT05536310
NCT03807921
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions